SH3BP1 and chronic myelogenous leukemia, BCR-ABL1 positive: To identify whether SH3BP1 and downstream Rac1 signaling are involved in drug sensitivity in CML, we investigated the role of SH3BP1 and Rac1 in nilotinib resistance using the K562 cell line.